| |
VA researchers develop biomed innovations in all areas of healthcare, from substance abuse treatments to visual impairment aids and more. License and commercialize VA innovations with no-cost help from TechLink. Learn about available technologies.
|
|
Today’s Big NewsJul 23, 2024 |
| By James Waldron Moderna recently became the latest biopharma to score an approval to prevent respiratory syncytial virus (RSV), but Merck & Co. hopes to be the next in line with new data showing a monoclonal antibody reduced the incidence of RSV-related infections in infants. |
|
|
|
By Nick Paul Taylor A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases. |
By Nick Paul Taylor Flagship Pioneering has thrown $50 million behind a push to create synthetic proteins that overcome the limitations of natural biologics. The money will support Abiologics, a biotech that has grown out of three years of work at Flagship to create a platform capable of birthing the new modality. |
Sponsored by CSafe Global How is the cold chain adapting to the cell and gene therapy boom? Emilio Frattaruolo, Vice President of Cell and Gene Therapies at CSafe, discusses the logistical challenges and innovations shaping the future of these revolutionary treatments. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More.
|
|
By Annalee Armstrong Revenue for clinical research services company IQVIA was boosted by 2.3% in the first six months of the year compared to the same period a year before, thanks to better-than-expected performance from the company’s technology and analytics solutions offerings. |
Sponsored by InMed Pharmaceuticals InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Angus Liu In a new head-to-head study, GSK's two-drug regimen Dovato showed comparable antiviral efficacy to Gilead's Biktarvy with a milder effect on body weight. |
By Emma Beavins Mental health advocates including the American Psychiatric Association met with the White House in July to call for Schedule IIN narcotics to be prescribed via telehealth without in-person requirements. If the pre-pandemic requirements are reinstated, patients and providers will face massive challenges, APA said. |
By Conor Hale Tulavi Therapeutics' de novo clearance covers an absorbable hydrogel that encases the end of a severed nerve, preventing it from trying to regenerate. |
By Nick Paul Taylor Sanofi has reached a critical milestone in its push to change how it is seen by the wider world. With the world’s media descending on Paris for the Olympics, the French drugmaker is ramping up for the “biggest corporate activation” in its history. |
By Heather Landi A widespread global IT outage impacted health systems, hospitals and clinics as electronic health record software has been knocked offline, forcing providers to cancel or delay non-emergency procedures and services. |
Fierce podcastsDon’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
